<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168153">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01894399</url>
  </required_header>
  <id_info>
    <org_study_id>HM-EMSI-102</org_study_id>
    <nct_id>NCT01894399</nct_id>
  </id_info>
  <brief_title>Study to Evaluate a Pharmacokinetic of HM61713 in Healthy Male Subjects</brief_title>
  <official_title>Phase Ⅰ Study to Assess the Safety, Tolerability, Pharmacokinetic Characteristics of HM61713 Tablet in Healthy Korean, Japanese and Caucasian</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design

        -  Open, escalating single-dose design.

        -  7 ascending dose cohorts

        -  In each cohorts, subjects will receive a single dose of HM61713.

        -  Main objective of this study is to evaluate the pharmacokinetics of HM61713 tablet.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives

        -  to evaluate the safety and tolereability of HM61713 tablet in healthy male subjects.

        -  to evaluate food effect on PK characteristics of HM61713 tablet in healthy male
           subjects.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Plasma/Urine PK parameters</measure>
    <time_frame>0-48 hrs</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax, AUC, Tmax, T1/2, fe, CL/F, CLR, Vd, MRT of HM61713 and Metaboletes(M1, M2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety data, including physical examinations, laboratory evaluation, ECGs, ICGs, vital signs, and adverse events.</measure>
    <time_frame>7 days after the investigational drug administration.</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg HM61713 single dose in Korean</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg HM61713 single dose in Korean</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg HM61713 single dose in Korean</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg HM61713 single dose in Japanese</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg HM61713 single dose in Japanese</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg HM61713 single dose in Caucasian</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg HM61713 single dose in Caucasian</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM61713 tablet</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers, age between 20 and 45

          -  Informed of the investigational nature of this study and voluntarily agree to
             participate in this study

          -  BMI of ＞18.5kg/m2 and ＜28kg/m2 subject

        Exclusion Criteria:

          -  Use of any prescription medication within 2 weeks prior to Day 1

          -  Use of any medication within 1 weeks prior to Day 1

          -  Has a severe medical history of hypersensitivity to drug

          -  Participation in another clinical study within 8 weeks days prior to start of study
             drug administration
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyung-Mi Park, PhD</last_name>
    <email>kmpark@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>In-Jin Jang, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>In-Jin Jang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 3, 2013</lastchanged_date>
  <firstreceived_date>July 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HM61713</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
